The California Department of Public Health has granted Immunovia, Inc., the American subsidiary of Immunovia AB, a Clinical and Public Health Laboratory license, allowing physicians in California to order the IMMray PanCan-d test for their patients.
LUND, Sweden, Aug. 11, 2022 /PRNewswire/ -- The California Department of Public Health has granted Immunovia, Inc., the American subsidiary of Immunovia AB (Nasdaq :IMMNOV) (Stockholm: IMMNOV), a Clinical and Public Health Laboratory license, allowing physicians in California to order the IMMray PanCan-d test for their patients.
“People at risk for pancreatic cancer need better tools for early detection. We are thrilled that this approval enables us to make IMMray PanCan-d available to clinicians in California who care for those at risk.” says Jeff Borcherding, Chief Executive Officer of Immunovia, Inc.
For more information, please contact:
Philipp Mathieu
CEO and President
Email: philipp.mathieu@immunovia.com
Karin Almqvist Liwendahl
Chief Financial Officer
Email: karin.almqvist.liwendahl@immunovia.com
The information was submitted for publication on August 10, 2022, at 09:55 am CET.
About Immunovia
Immunovia AB is a diagnostic company with the vision to revolutionize blood-based diagnostics and increase survival rates for patients with cancer.
Our first product, IMMray™ PanCan-d is the only blood test currently available specifically for the early detection of pancreatic cancer. The test has unmatched clinical performance. Commercialization of IMMray™ PanCan-d started in August 2021 in the USA and IMMray™ PanCan-d is offered as a laboratory developed test (LDT) exclusively through Immunovia, Inc. For more information see: www.immunoviainc.com.
Immunovia collaborates and engages with healthcare providers, leading experts and patient advocacy groups globally to make this test available to all high-risk pancreatic cancer groups.
The USA, the first market in which IMMray™ PanCan-d is commercially available, is the world’s largest market for the detection of pancreatic cancer with an estimated value of more than USD 4 billion annually.
Immunovia’s shares (IMMNOV) are listed on Nasdaq Stockholm. For more information, please visit www.immunovia.com.
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
| Press release (PDF) |
View original content:https://www.prnewswire.com/news-releases/immunovia-inc-issued-clinical-and-public-health-laboratory-license-from-california-dept-of-public-health-for-immray-pancan-d-test-301604178.html
SOURCE Immunovia AB
Company Codes: Bloomberg:IMMNOV@SS, ISIN:SE0006091997, RICS:IMMNOV.ST, Stockholm:IMMNOV
